MARKET WIREYahoo Finance • 1d ago
GH Research (GHRS) Stock May Look Stretched As Book Value Trails PriceYahoo Finance report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
Why GHRS Stock slipped -1.73% Today — RQD Quant Desk Flash
$20.50 -1.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.40
GH Research PLC (GHRS) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.43B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GHRS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, GH Research PLC (NASDAQ: GHRS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.50 (-1.73% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GHRS ranks #276 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GHRS compare to ANAB and TYRA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GHRS carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ANAB (AnaptysBio Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC 85.0%, cap $1.43B) and TYRA (Tyra Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B). Among the 5-stock peer group, GHRS leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GHRS?
▼
For GH Research PLC (GHRS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #276 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.40 (-0.50%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GHRS)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY GHRS SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 1% FCF Margin ($40.0M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$18.85+1.7% Next Q
41
Q2 (-2Q)Grade D$19.17+4.4% Next Q
44
Q3 (-1Q)Grade D$20.02+2.4% Next Q
46
CurrentGrade D$20.50-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GHRS Turnaround Squeeze
While GHRS currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.77) and Max Pain ($21.53) forces dealer call-delta covering toward $33.01.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GHRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GHRS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GHRS Stock slipped -1.73% Today — RQD Quant Desk Flash
GH Research PLC (GHRS) slipped -1.73% to $20.50, trading at 44% of its 52-week range ($12.04 – $31.44). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 44% of its 52-week range ($12.04 – $31.44) with RSI-14 at 48 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $20.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $40.0M annual free cash flow.
Live GHRS Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program (NASDAQ:GHRS)Seeking Alpha report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions LingerYahoo Finance report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 1d ago
GH Research PLC (GHRS) Gains 3.23% to $21.11, Testing the Midpoint of Its Recent Range - High Volume Stockshttps://www.siam.in/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
GH Research PLC (GHRS) Retreats 3.02% to $21.50, Drifting Toward Key Support - Stock Buy Zonehttps://www.dars.gov.et/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
GH Research PLC (GHRS) Holds Steady at $18.15 as Shares Consolidate Between Key Technical Boundaries - Momentum Breakout Ideashttps://www.siam.in/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 2d ago
GH Research PLC (GHRS) Rises 1.95% to $20.41, Pressing Toward the $21.43 Ceiling - Inside Day Breakouthttps://www.dars.gov.et/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GHRS)
- ✓Walkthrough of GHRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GHRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.49%▼ DESCENDING CHANNEL
2026-11-03O $21.50H $21.50L $20.50C $20.50VOL 305.4K
RES: $26.49SUP: $16.82SMA50: $23.77SMA200: $21.59
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GHRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on GHRS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GHRS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GHRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GHRS)
Health Care Rank #276 of 1015
⚔️ ANAB vs GHRS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GHRS vs. ANAB, TYRA, PCRX, KRSA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, GH Research PLC (GHRS) ranks #276 by composite RQD confidence (49/100, grade D) and #306 by equity capitalization ($1.43B). Within this direct 5-issuer industry benchmark cohort, GHRS leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PCRX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with GHRS at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GHRS
ACTIVE
GH Research PLC | D | 49/100 | — | — | — | -1.73% | $1.43B | Benchmark Subject |
| ANAB AnaptysBio Inc. | C- | 60/100 | — | — | 85.0% | -2.84% | $1.43B | /anab-vs-ghrs → |
| TYRA Tyra Biosciences Inc. | E | 30/100 | — | — | -35.0% | +1.23% | $1.45B | /tyra-vs-ghrs → |
| PCRX Pacira BioSciences Inc. | C | 65/100 | — | 79.4% | 1.7% | +0.03% | $1.45B | /pcrx-vs-ghrs → |
| KRSA Korsana Biosciences Inc. | D- | 38/100 | — | — | -5.7% | +5.04% | $1.37B | /krsa-vs-ghrs → |
2. GHRS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTGH Research PLC (GHRS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.43B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. GHRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, GH Research PLC (NASDAQ: GHRS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.50 (-1.73% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GHRS ranks #276 in composite RQD confidence.
How does GHRS compare to ANAB and TYRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GHRS carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ANAB (AnaptysBio Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC 85.0%, cap $1.43B) and TYRA (Tyra Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B). Among the 5-stock peer group, GHRS leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GHRS?
For GH Research PLC (GHRS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #276 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GHRS trading relative to its 50-day, 200-day, and 52-week technical levels?
GHRS last traded at $20.50 (-1.73% on volume of 542,857 shares), positioning the stock -13.76% below its 50-day simple moving average ($23.77) and -5.05% below its 200-day simple moving average ($21.59). Across its 52-week range of $12.04 to $31.44, GHRS sits at the 43.6% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($18.04 to $22.96).
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ SEC XBRL & RQD VERIFIED
GHRS — GH Research PLC: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
GH Research PLC (GHRS) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $20.50 (-1.73% 1D, market capitalization $1.43B).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
GH Research PLC (GHRS) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $1.43B, gross margin of —, operating margin of —, and return on invested capital (ROIC) of —.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $12.04 – $31.44 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The supply chain is recorded as "NONE," with no upstream or downstream links and no proprietary signals. Sector classification is Health Care, industry Biotechnology: Pharmaceutical Preparations. No sector correlations, bottleneck dependencies, or 2nd-order ripples are available in source data. An investor should note that the absence of mapped links is itself a data limitation, not evidence of an absence of dependencies.
- Key Question #1: Can GHRS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $31.44 52-week high?
- Key Question #3: How sensitive is GHRS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
GHRS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for GH Research PLC (GHRS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price Yahoo Finance report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program (NASDAQ:GHRS) Seeking Alpha report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger Yahoo Finance report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 1d ago
GH Research PLC (GHRS) Gains 3.23% to $21.11, Testing the Midpoint of Its Recent Range - High Volume Stocks https://www.siam.in/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
GH Research PLC (GHRS) Retreats 3.02% to $21.50, Drifting Toward Key Support - Stock Buy Zone https://www.dars.gov.et/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
GH Research PLC (GHRS) Holds Steady at $18.15 as Shares Consolidate Between Key Technical Boundaries - Momentum Breakout Ideas https://www.siam.in/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 2d ago
GH Research PLC (GHRS) Rises 1.95% to $20.41, Pressing Toward the $21.43 Ceiling - Inside Day Breakout https://www.dars.gov.et/ report covering GH Research PLC (GHRS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GHRS Bull vs. Bear Conversation Board — What's Your Call at $20.50?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GHRS 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $23.99 (+15.0%)
📌 Pinned Debate The forensic balance sheet scores 13 / 20 with an Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5, the strongest pillar in
The forensic balance sheet scores 13 / 20 with an Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5, the strongest pillar in the rating.. When you look under the hood at GHRS, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $31.44. My 12M target is $23.99.
ArenaChamp_24 🐂 BULL
@AlphaFlow_Cap Agree on the RQD 49/100 quality, though with 1.0 beta I'm scaling in with half-size at $20.86 and keeping dry powder in case we test $19.40.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $17.52 (-16.0%)
Spot @ $20.86 With ROIC at 0% and FCF yield at 0%, the cash engine pillar scores only 12 / 20 and the rating carries a distribution warning.
Here is the bear case nobody on the bull side wants to address on GHRS: With ROIC at 0% and FCF yield at 0%, the cash engine pillar scores only 12 / 20 and the rating carries a distribution warning.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.